Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Relapse prevention in schizophrenia: second-generation antipsychotics versus first-generation antipsychotics
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Relapse prevention in schizophrenia: second-generation antipsychotics versus first-generation antipsychotics
Admin Tue Dec 06, 2011 1:48 am
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia.
Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability.
Across 23 studies (n=4504, mean duration=61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring ≥3 trials.
Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR=0.80, CI: 0.70-0.91, P=0.0007, I(2)=37%; NNT=17, CI: 10-50, P=0.003).
SGAs were also superior regarding relapse at 3, 6 and 12 months (P=0.04, P<0.0001, P=0.0001), treatment failure (P=0.003) and hospitalization (P=0.004).
SGAs showed trend-level superiority for dropout owing to intolerability (P=0.05).
Superiority of SGAs regarding relapse was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses.
There was no significant heterogeneity or publication bias.
The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.
Read the full article here:- http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2011143a.html
We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia.
Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability.
Across 23 studies (n=4504, mean duration=61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring ≥3 trials.
Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR=0.80, CI: 0.70-0.91, P=0.0007, I(2)=37%; NNT=17, CI: 10-50, P=0.003).
SGAs were also superior regarding relapse at 3, 6 and 12 months (P=0.04, P<0.0001, P=0.0001), treatment failure (P=0.003) and hospitalization (P=0.004).
SGAs showed trend-level superiority for dropout owing to intolerability (P=0.05).
Superiority of SGAs regarding relapse was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses.
There was no significant heterogeneity or publication bias.
The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.
Read the full article here:- http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2011143a.html
Admin- Admin
- Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia -
Similar topics» Older Antipsychotics Trump Newer Agents for Schizophrenia
» Quiz Time: Opioid Relapse Prevention
» Efficacy Among Second-Generation Antidepressants is About the Same
» Second-Generation Antiepileptic Drugs and Pregnancy: A Guide For Clinicians.
» Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis
» Quiz Time: Opioid Relapse Prevention
» Efficacy Among Second-Generation Antidepressants is About the Same
» Second-Generation Antiepileptic Drugs and Pregnancy: A Guide For Clinicians.
» Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
» L-Methylfolate: Who Will benefit
» Vitamins & Supplements in Clinical Practice.
» Imaging Biomarkers for Outcomes in Mild TBI
» Q.5 Clozapine Neutopenia
» Treating Disorders!
» Cortical Abnormalities in Adults & Adolescents with MDD
» Efficacy of Antipsychotics in Pediatric Acute Mania
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?